The President-elect seemed relaxed and even polite to reporters in his first – and marathon – press event since his Nov. 5 ...

Shares of pharmacy benefit managers fell Monday after President-elect Donald Trump said he plans to “knock out” drug-industry ...

The $16.5 billion take-private deal can now be completed, and along with it Novo Nordisk’s related acquisition of three ...

Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling ...

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

Eli Lilly LLY announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

The fundamentals of Novo and Lilly do look robust, but it is always wise to avoid putting all of your eggs in one basket.

Health-care companies fell amid concerns about regulation from the Trump administration. A retreat for UnitedHealth Group continued after President-elect Donald Trump vowed to root "middle men" out of ...

Weight loss drugs, compounding, vitamin D, and AI all piqued readers’ interest — and sometimes, ire — this past year.

2024 was one of the most eventful years for the pharmaceutical, biotech, life sciences and medical marketing industries.